Alvotech has given Japanese firm Fuji Pharma exclusive commercial rights to its biosimilars portfolio in Japan. Under the deal, Alvotech will be responsible for developing and supplying biosimilars within its pipeline that currently includes rivals to AbbVie’s Humira (adalimumab) and Janssen’s Stelara (ustekinumab), the latter using perfusion fermentation technology.
Alvotech has given Japanese firm Fuji Pharma exclusive commercial rights to its biosimilars portfolio in Japan. Under the deal, Alvotech will be responsible for developing and supplying biosimilars within its pipeline that currently includes rivals to AbbVie’s Humira (adalimumab) and Janssen’s Stelara (ustekinumab), the latter using perfusion fermentation technology.
Fuji – which was among the pioneers in the Japanese biosimilars sector, having secured approval for filgrastim in 2012 through...
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
